Log in
RegisterBE and drop out subjects Phoenix [General Statistics]
We have implemented a 3 way cross-over balanced design (Williams, 6 sequences) for a fed, fasted, sprinkled on food bioequivalence study. It is not a highly variable drug (CV ~15%). The study has gone well and the results are unambiguous. We did lose one subject at PERIOD 3. I am wondering whether I should exclude the other two treatments for this subject prior to BE data analysis in Phoenix. Or should I include all the data I have. Or indeed do the data analysis both ways.
This work is a registration study and will be submitted here to the FDA.
Angus
This work is a registration study and will be submitted here to the FDA.
Angus
Complete thread:
- BE and drop out subjects PhoenixAngusMcLean 2014-01-24 00:02
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- Keeping subjects in mixed-effects models Helmut 2014-01-24 04:18
- Keeping subjects in mixed-effects models AngusMcLean 2014-01-24 14:26
- Keeping subjects in mixed-effects models Helmut 2014-01-24 15:28
- Keeping subjects in mixed-effects models AngusMcLean 2014-01-24 16:28
- Keeping subjects in mixed-effects models Helmut 2014-01-24 16:59
- Keeping subjects in mixed-effects models AngusMcLean 2014-01-26 15:58
- SAP Helmut 2014-01-26 16:25
- Keeping subjects in mixed-effects models AngusMcLean 2014-01-24 16:28
- Keeping subjects in mixed-effects models Helmut 2014-01-24 15:28
- Keeping subjects in mixed-effects models AngusMcLean 2014-01-24 14:26
- Keeping subjects in mixed-effects models Helmut 2014-01-24 04:18
Ing. Helmut Schütz